Docetaxel for Non-small Cell Lung Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Non-small Cell Lung Cancer+7 More
Docetaxel - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing the combination of two drugs, ceritinib and docetaxel, to see if it is effective and safe for people with NSCLC.

Eligible Conditions
  • Non-small Cell Lung Cancer
  • Malignant Neoplasms
  • Non-Small Cell Lung Carcinoma
  • Lung Cancers

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Non-small Cell Lung Cancer

Study Objectives

2 Primary · 2 Secondary · Reporting Duration: Up to 30 months

Up to 30 months
Overall Survival (OS)
Phase Ib: Overall Response (OR)
Progression-free Survival (PFS)
Up to 6 months
Phase I: Maximum Tolerated Dose (MTD)

Trial Safety

Safety Progress

1 of 3

Other trials for Non-small Cell Lung Cancer

Trial Design

2 Treatment Groups

Phase I Dose Escalation
1 of 2
Phase Ib Dose Expansion
1 of 2
Experimental Treatment

48 Total Participants · 2 Treatment Groups

Primary Treatment: Docetaxel · No Placebo Group · Phase 1

Phase I Dose EscalationExperimental Group · 2 Interventions: Docetaxel, Ceritinib · Intervention Types: Drug, Drug
Phase Ib Dose ExpansionExperimental Group · 2 Interventions: Docetaxel, Ceritinib · Intervention Types: Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Docetaxel
FDA approved
Tyrosine
FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 30 months

Who is running the clinical trial?

H. Lee Moffitt Cancer Center and Research InstituteLead Sponsor
489 Previous Clinical Trials
123,322 Total Patients Enrolled
4 Trials studying Non-small Cell Lung Cancer
202 Patients Enrolled for Non-small Cell Lung Cancer
Andreas Saltos, M.D.Principal InvestigatorH. Lee Moffitt Cancer Center and Research Institute

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a performance status of 0 or 1.
You are willing and able to comply with scheduled study visits and procedures.
You have advanced/metastatic Non-small Cell Lung Cancer (NSCLC), stage IIIB/IV.
You have received at least one prior regimen containing a platinum-based agent, and at least one prior regimen containing a taxane

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 26th, 2021

Last Reviewed: October 29th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.